PT - JOURNAL ARTICLE AU - Hosseini, Bayan AU - McCarty, Rachel AU - Zins, Marie AU - Goldberg, Marcel AU - Ribet, Céline AU - Schreiver, Ines AU - Ezzedine, Khaled AU - Schüz, Joachim AU - Foerster, Milena TI - Cohort profile: The Cancer Risk Associated with the Body Art of Tattooing (CRABAT) study AID - 10.1101/2024.10.28.24316120 DP - 2024 Jan 01 TA - medRxiv PG - 2024.10.28.24316120 4099 - http://medrxiv.org/content/early/2024/11/01/2024.10.28.24316120.short 4100 - http://medrxiv.org/content/early/2024/11/01/2024.10.28.24316120.full AB - Tattooing, involving the injection of pigments into the skin, has become increasingly popular, with up to 40% of individuals under 40 years old tattooed in high-income countries. Despite regulatory measures, tattoo inks may contain hazardous substances such as polycyclic aromatic hydrocarbons, primary aromatic amines, and metallic impurities, many of which are classified as carcinogens. Research on systemic health risks, particularly cancer, associated with intradermal ink exposure remains limited. Complications like contact allergies and inflammatory skin reactions are more frequently reported among tattooed individuals. However, cancer risks from tattooing, especially for internal cancers like lymphoma, are challenging to assess. Existing case-control studies indicate mixed findings regarding hematologic cancers, with one large study reporting a 20% increased lymphoma risk among tattooed individuals in the first two years post-tattooing.Here, we present the Cancer Risk Associated with the Body Art of Tattooing (CRABAT) study, that is, to our knowledge, the first larger study that prospectively investigates tattoo-related cancer risks. CRABAT follows up over 110,000 participants for long-term health effects within the French Constances cohort with objective cancer data linkage. Of ∼13,000 participants that were tattooed in 2020, detailed tattoo exposure assessment via a validated tattoo exposure questionnaire was conducted in 2023 (response rate >60%). With its robust dataset through linkage to the Constances variable pool, CRABAT enables the analysis of exposure-response relationships, and addresses potential confounders such as sociodemographic and lifestyle factors, and alternative pathways such as tattoo-related infections. Body word count: 2498 wordsCompeting Interest StatementThe authors have declared no competing interest.Funding StatementThe CRABAT study was supported by the French National Cancer Institute (INCa grant No 2021-137). None of these funding sources had any role in the design of the study, collection and analysis of data or decision to publishThe Constances cohort study was supported and funded by the French national health insurance fund (Cnam). Constances is a national infrastructure for biology and health and benefits from a grant from the French national agency for research (ANR-11-INBS-0002). Constances is also partly funded to a small extent by industrial companies, notably in the healthcare sector, within the framework of Public-Private Partnerships (PPP).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The IARC Ethics Committee gave ethical approval for this work. The French Data Protection Authorit CNIL waived ethical approval for this work. The Institutional review board (IRB) of the French Institute of Health (Inserm) gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData are not publicly available and can be obtained from third parties. Access to the data is subject to the submission of a research project proposal, which will be reviewed by the CONSTANCES International Scientific Committee and must be approved by the Institutional Steering Committee.